Department of Biostatistics, Institut Curie, PSL Research University, Saint-Cloud, France.
Department of Genetics, Institut Curie, PSL Research University, Department of Genetics, Paris, France.
JAMA Ophthalmol. 2020 Aug 1;138(8):843-850. doi: 10.1001/jamaophthalmol.2020.2100.
Retinoblastoma (RB) is the most common pediatric intraocular neoplasm. RB is a complex model in which atypical pathogenic variants, modifier genes, imprinting, and mosaicism are known to be associated with the phenotype. In-depth understanding of RB therefore requires large genotype-phenotype studies.
To assess the association between genotype and phenotype in patients with RB.
DESIGN, SETTING, AND PARTICIPANTS: This single-center, retrospective cohort study, conducted from January 1, 2000, to September 30, 2017, enrolled 1404 consecutive ascertained patients with RB who consulted an oncogeneticist. All patients had their genotype and phenotype recorded. Statistical analysis was performed from July 1, 2018, to December 31, 2018.
RB1 germline and somatic pathogenic variant types, family history, and disease presentation characteristics (ie, age at diagnosis, sex, laterality, and International Intraocular Retinoblastoma Classification group).
Among 1404 patients with RB (734 [52.3%] female; mean [SD] age, 20.2 [21.2] months), 866 cases (61.7%) were unilateral and 538 cases (38.3%) were bilateral. Loss of function variants were found throughout the coding sequence, with 259 of 272 (95.2%) somatic pathogenic variants and 537 of 606 (88.6%) germline pathogenic variants (difference, 6.6%; 95% CI, 4.0%-9.2%; P < .001) after excluding tumor-specific pathogenic variants (ie, promoter methylation and loss of heterozygosity); a novel low-penetrance region was identified in exon 24. Compared with germline pathogenic variants estimated to retain RB protein expression, germline pathogenic variants estimated to abrogate RB protein expression were associated with an earlier mean (SD) age at diagnosis (12.3 [11.3] months among 457 patients vs 16.3 [13.2] months among 55 patients; difference, 4 months; 95% CI, 1.9-6.1 months; P = .01), more frequent bilateral involvement (84.2% among 452 patients vs 65.2% among 45 patients; difference, 18.9%; 95% CI, 14.5%-23.3%; P < .001), and more advanced International Intraocular Retinoblastoma Classification group (85.3% among 339 patients vs 73.9% among 34 patients; difference: 11.4%; 95% CI, 6.5%-16.3%; P = .047). Among the 765 nongermline carriers of an RB1 pathogenic variant, most were female (419 females [54.8%] vs 346 males [45.2%]; P = .008), and males were more likely to have bilateral RB (23 males [71.4%] vs 12 females [34.3%]; P = .01).
These results suggest that RB risk is associated with the germline pathogenic variant and with maintenance of RB protein and that there is a sex-linked mechanism for nongermline carriers.
视网膜母细胞瘤(RB)是最常见的小儿眼内肿瘤。RB 是一个复杂的模型,已知异常的致病性变异、修饰基因、印迹和嵌合性与表型有关。因此,深入了解 RB 需要进行大型的基因型-表型研究。
评估 RB 患者的基因型与表型之间的关联。
设计、设置和参与者:这是一项单中心、回顾性队列研究,于 2000 年 1 月 1 日至 2017 年 9 月 30 日进行,纳入了 1404 名连续确诊的 RB 患者,他们咨询了肿瘤遗传学家。所有患者的基因型和表型均有记录。统计分析于 2018 年 7 月 1 日至 2018 年 12 月 31 日进行。
RB1 种系和体细胞致病性变异类型、家族史和疾病表现特征(即诊断时的年龄、性别、侧别和国际眼内视网膜母细胞瘤分类组)。
在 1404 名 RB 患者(734 名女性[52.3%];平均[SD]年龄,20.2[21.2]个月)中,866 例(61.7%)为单侧,538 例(38.3%)为双侧。在整个编码序列中发现了功能丧失变异,272 个体细胞致病性变异中有 259 个(95.2%)和 606 个种系致病性变异中有 537 个(88.6%)(差异,6.6%;95%CI,4.0%-9.2%;P<0.001),排除肿瘤特异性致病性变异(即启动子甲基化和杂合性丢失)后;在 24 号外显子中发现了一个新的低外显率区域。与估计保留 RB 蛋白表达的种系致病性变异相比,估计破坏 RB 蛋白表达的种系致病性变异与更早的平均(SD)诊断年龄相关(457 例患者为 12.3[11.3]个月,55 例患者为 16.3[13.2]个月;差异,4 个月;95%CI,1.9-6.1 个月;P=0.01),更频繁的双侧受累(452 例患者为 84.2%,45 例患者为 65.2%;差异,18.9%;95%CI,14.5%-23.3%;P<0.001),以及更高级别的国际眼内视网膜母细胞瘤分类组(339 例患者为 85.3%,34 例患者为 73.9%;差异:11.4%;95%CI,6.5%-16.3%;P=0.047)。在 765 名非 RB1 种系携带者中,大多数是女性(419 名女性[54.8%]比 346 名男性[45.2%];P=0.008),男性更有可能双侧 RB(23 名男性[71.4%]比 12 名女性[34.3%];P=0.01)。
这些结果表明,RB 风险与种系致病性变异以及 RB 蛋白的维持有关,并且非种系携带者存在性别相关的机制。